Market Assessment for a Palladium Membrane Deuteration Reactor

点击翻译按钮获取中文摘要

Our team is developing an electrochemical reactor that leverages the unique properties of a thin palladium membrane to perform reductive deuteration on organic substrates. Our reactor is favourable compared to known synthetic methods because: i) the reactor uses benign reagents; ii) the reactions proceed at room temperature and pressure; iii) the products are produced quantitatively; iv) the reaction is site-selective for certain bonds; v) no product separation is required. This system has the potential to benefit to the pharmaceutical industry because deuteration of a drug can slow the metabolism of a bioactive molecule and increase the overall efficacy. This link between deuteration and the properties for bio-active molecules is established, and the United States Food and Drug Administration approved the first deuterated drug, deutetetrabenazine, in 2017. Several other deuterated versions of common drugs are currently in phase II and III clinical trials. This proposal outlines our plan to undertake a market study in conjunction with UBC's University Industry Liaison Office and Adventus Research Consultants (Guelph, ON) to better understand the market potential of our invention. This study will encompass both primary and secondary research. The final deliverable will be a report from Adventus that informs our commercialization strategy as we develop the technology.